Edition:
United States

Insight: From cakes to tech, bold startups defy Portugal crisis

Photographer
RAFAEL MARCHANTE

An employee moves a baking tray at an outlet of The Portuguese Bakery in Lisbon December 21, 2012. REUTERS/Rafael Marchante

An employee moves a baking tray at an outlet of The Portuguese Bakery in Lisbon December 21, 2012. REUTERS/Rafael Marchante
Close
1 / 6
Photographer
RAFAEL MARCHANTE

Nuno Carvalho (R), 34, CEO of The Portuguese Bakery, speaks with a customer at one of its outlets in Lisbon December 21, 2012. Few things encapsulate Portugal better than its bakeries, where people from all walks of life mingle over coffee and cake. So when a whole new chain emerges in the depths of an economic crisis, it sends a glimmer of hope. REUTERS/Rafael Marchante

Nuno Carvalho (R), 34, CEO of The Portuguese Bakery, speaks with a customer at one of its outlets in Lisbon December 21, 2012. Few things encapsulate Portugal better than its bakeries, where people from all walks of life mingle over coffee and cake. So when a whole new chain emerges in the depths of an economic crisis, it sends a glimmer of hope. REUTERS/Rafael Marchante
Close
2 / 6
Photographer
RAFAEL MARCHANTE

Nuno Carvalho, 34, CEO of The Portuguese Bakery, poses at one of its outlets in Lisbon December 21, 2012. REUTERS/Rafael Marchante

Nuno Carvalho, 34, CEO of The Portuguese Bakery, poses at one of its outlets in Lisbon December 21, 2012. REUTERS/Rafael Marchante
Close
3 / 6
Photographer
RAFAEL MARCHANTE

Nuno Carvalho, 34, CEO of The Portuguese Bakery, clears tables on a terrace at one of its outlets in Lisbon December 21, 2012. REUTERS/Rafael Marchante

Nuno Carvalho, 34, CEO of The Portuguese Bakery, clears tables on a terrace at one of its outlets in Lisbon December 21, 2012. REUTERS/Rafael Marchante
Close
4 / 6
Photographer
RAFAEL MARCHANTE

A laboratory worker handles instruments at the Cell2B biomedical company near Lisbon December 18, 2012. Cell2B is preparing for clinical trials of promising cell therapies aimed at eliminating transplant rejection in humans, after which the founders do not rule out a share offering. REUTERS/Rafael Marchante

A laboratory worker handles instruments at the Cell2B biomedical company near Lisbon December 18, 2012. Cell2B is preparing for clinical trials of promising cell therapies aimed at eliminating transplant rejection in humans, after which the founders do not rule out a share offering. REUTERS/Rafael Marchante
Close
5 / 6
Photographer
RAFAEL MARCHANTE

Laboratory instruments are seen at the Cell2B biomedical company near Lisbon December 18, 2012. Cell2B is preparing for clinical trials of promising cell therapies aimed at eliminating transplant rejection in humans, after which the founders do not rule out a share offering. Picture taken December 18, 2012. REUTERS/Rafael Marchante

Laboratory instruments are seen at the Cell2B biomedical company near Lisbon December 18, 2012. Cell2B is preparing for clinical trials of promising cell therapies aimed at eliminating transplant rejection in humans, after which the founders do not rule out a share offering. Picture taken December 18, 2012. REUTERS/Rafael Marchante
Close
6 / 6

All Collections

El Cajon protests after police shooting

Thursday, September 29, 2016

All Collections

Will and Kate visit Canada

Thursday, September 29, 2016

All Collections

Photos of the week

Thursday, September 29, 2016

All Collections

Typhoon Megi strikes

Thursday, September 29, 2016

All Collections

Best of Paris Fashion Week

Thursday, September 29, 2016

All Collections

Mourning Shimon Peres

Thursday, September 29, 2016

All Collections

Wildfire burns in Santa Cruz mountains

Wednesday, September 28, 2016

All Collections

Siege of Aleppo

Wednesday, September 28, 2016